FDA Assigns a Newborn Screening Test to Class II
Published Date: 6/26/2025
Rule
Summary
The FDA is officially putting the lysosomal storage disorder newborn screening test system into a safer, easier-to-manage category called Class II. This change helps make sure the test is safe and effective while speeding up access to new, helpful devices for babies. The new rules took effect on June 26, 2025, making it simpler and less costly for companies to bring these lifesaving tests to hospitals.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Newborn Screening Tests Reclassified to Class II
The FDA officially classified the lysosomal storage disorder newborn screening test system as Class II (special controls) effective June 26, 2025, with the classification applicable on February 3, 2017. The device is subject to premarket notification under section 510(k), and FDA states this will reduce regulatory burdens and help speed patient access to these tests.
Required Clinical Studies and Lab Performance Rules
Manufacturers must perform clinical validation using well-characterized clinical specimens from the intended newborn population and testing by representative operators, and must demonstrate things like reference intervals, limit of detection/quantitation, carryover/drift, and imprecision. The rule requires imprecision studies using sample panels from at least three reagent lots and at least three instruments over more than 20 testing days, and prohibits reporting sample concentrations below the limit of quantitation.
Labeling Must Disclose Limits and Error Rates
Labeling for these tests must include a warning that the test is not intended to diagnose lysosomal storage disorders and must state that results should be used with other clinical findings and confirmed by alternative methods. Labels must also include detailed device performance data from the clinical study, including the false positive rate, the false negative rate, and performance in relevant subgroups (for example: age at collection, birth weight, sex, gestational age, race, ethnicity).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-11780, Protection of Stratospheric Ozone; CFR Correction
The EPA fixed some technical details in the rules about safe refrigerants that protect our ozone layer. This update adds important footnotes explaining safety and design standards for vehicle air conditioners, making sure everyone uses the right stuff the right way. If you work with refrigerants, these clarifications help keep things clear and safe—no new costs or deadlines, just better info!
Next: 2025-11791, Medical Devices; Radiology Devices; Classification of the Cream for X-Ray Attenuation
The FDA is officially classifying the cream used to block X-rays as a Class II device with special safety rules. This change makes it easier and safer for patients to get this innovative cream by lowering regulatory hurdles. The new classification is effective June 26, 2025, and helps companies bring these creams to market faster without extra costs.